Skip to content

Study · Not a test of the peptide alone · 2022

9 results

A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.

Tham LS, Pantalone KM, Dungan K, Munir K, Tang CC, Konig M, Kwan AYM

Diabetes, obesity & metabolism8 Nov 2021Cited by 11 (Europe PMC)

PMID34697882 (opens in a new tab)PMCIDPMC9298861 (opens in a new tab)DOI10.1111/dom.14582 (opens in a new tab)PepBankPUB-34697882
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    Computer models predicted HbA1c reductions up to 1.55% from baseline with semaglutide 0.5 mg at 26 weeks.

    In plain wordsComputer models predicted HbA1c reductions up to 1.55% with semaglutide 0.5 mg after 26 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePredicted HbA1c at week 26
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.55%
    semaglutide 0.5 mg, up to this reduction

    Source sentences

    Summary
    At 26 weeks, model-predicted mean changes from baseline in HbA1c and weight for semaglutide 0.5 mg were up to -1.55% and -3.44 kg, respectively.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    Computer models predicted weight reductions up to 3.44 kg from baseline with semaglutide 0.5 mg at 26 weeks.

    In plain wordsComputer models predicted weight reductions up to 3.44 kg with semaglutide 0.5 mg after 26 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePredicted weight at week 26
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −3.44 kg
    semaglutide 0.5 mg, up to this reduction

    Source sentences

    Summary
    At 26 weeks, model-predicted mean changes from baseline in HbA1c and weight for semaglutide 0.5 mg were up to -1.55% and -3.44 kg, respectively.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoEfficacy outcome

    Computer models predicted a further HbA1c reduction of 0.19% after switching from semaglutide to dulaglutide 3.0 mg.

    In plain wordsComputer models predicted HbA1c fell a further 0.19% after switching from semaglutide to dulaglutide 3.0 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePredicted additional HbA1c reduction with dulaglutide 3.0 mg
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Further HbA1c reduction
    0.19%
    at week 52 after switch

    Source sentences

    Summary
    After switching to dulaglutide 3.0 mg, further reductions were 0.19% and 1.40 kg, respectively, at 52 weeks.
    4 context sentences
    Summary · context
    At 26 weeks, model-predicted mean changes from baseline in HbA1c and weight for semaglutide 0.5 mg were up to -1.55% and -3.44 kg, respectively.
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoEfficacy outcome

    Computer models predicted a further weight reduction of 1.40 kg after switching from semaglutide to dulaglutide 3.0 mg.

    In plain wordsComputer models predicted weight fell a further 1.40 kg after switching from semaglutide to dulaglutide 3.0 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePredicted additional weight reduction with dulaglutide 3.0 mg
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Further weight reduction
    1.4 kg
    at week 52 after switch

    Source sentences

    Summary
    After switching to dulaglutide 3.0 mg, further reductions were 0.19% and 1.40 kg, respectively, at 52 weeks.
    4 context sentences
    Summary · context
    At 26 weeks, model-predicted mean changes from baseline in HbA1c and weight for semaglutide 0.5 mg were up to -1.55% and -3.44 kg, respectively.
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 05Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    Computer models predicted an HbA1c change of -1.84% from baseline with semaglutide 1.0 mg at 26 weeks.

    In plain wordsComputer models predicted HbA1c fell 1.84% with semaglutide 1.0 mg after 26 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePredicted HbA1c at week 26
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.84%
    semaglutide 1.0 mg at week 26

    Source sentences

    Summary
    Predicted mean HbA1c and weight changes for semaglutide 1.0 mg at 26 weeks were -1.84% and -4.96 kg, respectively; after switching to dulaglutide 4.5 mg, HbA1c was maintained with additional weight reduction of up to 0.57 kg at 52 weeks.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    Computer models predicted a weight change of -4.96 kg from baseline with semaglutide 1.0 mg at 26 weeks.

    In plain wordsComputer models predicted weight fell 4.96 kg with semaglutide 1.0 mg after 26 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePredicted weight at week 26
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −4.96 kg
    semaglutide 1.0 mg at week 26

    Source sentences

    Summary
    Predicted mean HbA1c and weight changes for semaglutide 1.0 mg at 26 weeks were -1.84% and -4.96 kg, respectively; after switching to dulaglutide 4.5 mg, HbA1c was maintained with additional weight reduction of up to 0.57 kg at 52 weeks.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoEfficacy outcome

    Computer models predicted HbA1c maintenance after switching from semaglutide 1.0 mg to dulaglutide 4.5 mg.

    In plain wordsComputer models predicted stable HbA1c after switching from semaglutide 1.0 mg to dulaglutide 4.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePredicted HbA1c maintenance with dulaglutide 4.5 mg
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Predicted mean HbA1c and weight changes for semaglutide 1.0 mg at 26 weeks were -1.84% and -4.96 kg, respectively; after switching to dulaglutide 4.5 mg, HbA1c was maintained with additional weight reduction of up to 0.57 kg at 52 weeks.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  8. 08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoEfficacy outcome

    Computer models predicted additional weight reduction up to 0.57 kg after switching from semaglutide 1.0 mg to dulaglutide 4.5 mg.

    In plain wordsComputer models predicted further weight reduction up to 0.57 kg after switching from semaglutide to dulaglutide 4.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePredicted additional weight reduction with dulaglutide 4.5 mg
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Additional weight reduction
    ≤ 0.57 kg
    up to this reduction at week 52

    Source sentences

    Summary
    Predicted mean HbA1c and weight changes for semaglutide 1.0 mg at 26 weeks were -1.84% and -4.96 kg, respectively; after switching to dulaglutide 4.5 mg, HbA1c was maintained with additional weight reduction of up to 0.57 kg at 52 weeks.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  9. 09Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoEfficacy outcome

    Computer models predicted preserved glycaemic control after switching from semaglutide 1.0 mg to dulaglutide 3.0 mg.

    In plain wordsComputer models predicted stable glucose control after switching from semaglutide 1.0 mg to dulaglutide 3.0 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePredicted glycaemic control with dulaglutide 3.0 mg
    Study

    n: not reported in source

    Exposure-response simulations using SUSTAIN and AWARD-11 data
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycaemic control was preserved when switching from semaglutide 1.0 mg to dulaglutide 3.0 mg.
    3 context sentences
    Summary · context
    HbA1c and body weight time-course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD-11 trial for dulaglutide.
    Summary · context
    Simulations were conducted for HbA1c and body weight over 52 weeks.
    Summary · context
    In the initial 26 weeks, semaglutide was initiated at 0.25-mg and titrated to 0.5- or 1.0-mg QW via 4-weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75- or 1.5-mg QW and escalated to 3.0- or 4.5-mg QW via 4-weekly stepwise titration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.